Dong-A Surpasses 800 Bn-won in Annual Sales in 2009
Febrary 08 2010 --In 2009, Dong-A achieved 14.1 percent growth in sales for a total of 801 billion 60 million won. Operating income rose 12.5 percent to 91 billion 925 million won, and net income soared 46.5 percent to 63 billion 433 million won. This tremendous performance was made possible by Dong-A's balanced growth at home and abroad. It did well not only in its domestic hospital business (prescription drugs) and pharmacy business (over-the-counter drugs), but also with exports.
more
Health Discovery Corporation Partners with Major New York City Pancreatic Cancer Center to Develop a New Molecular Diagnostic Test for the Early Detection of Pancreatic Cancer
Savannah, Ga. -- February 5, 2010 -- Health Discovery Corporation (OTCBB: HDVY) announced today that the Company has entered into an exclusive agreement with the Pancreas, Biliary and Liver Surgery Center of New York at Saint Vincent Catholic Medical Centers in New York City to develop new molecular diagnostic tests for the early detection of pancreatic cancer. The Pancreas, Biliary and Liver Surgery Center is under the leadership of Drs. Michael Wayne, Franklin Kassim and Avram Cooperman.
more
Flutiform US NDA update
LONDON, UK, 5 February 2010 - SkyePharma PLC (LSE: SKP) today announces that the New Drug Application (NDA) for Flutiform(TM) (fluticasone propionate/formoterol fumarate) in the U.S. is being transferred to SkyePharma.
more